Capricor Therapeutics Inc (NASDAQ:CAPR) stock is trading higher on Monday as investors react to the FDA’s continued review of deramiocel update.
The U.S Food and Drug Administration (FDA) extended the PDUFA target action date for deramiocel, setting a new target of November 22.
Investors are probably reacting because the FDA did not issue a Complete Response Letter requesting additional data or studies to approve the drug.
The extended timeline still keeps hopes for the Duchenne muscular dystrophy cell therapy.
CAPR Jumps On FDA PDUFA Extension For Deramiocel
